{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Metastases to liver","Metastatisk tarmkræft der udgår fra tyk- eller endetarm","Metastatic colon or rectal cancer","Colorectal cancer stage IV"],"disease":["Colorectal Cancer Stage Iv","Metastatisk Tarmkræft Der Udgår Fra Tyk- Eller Endetarm","Metastases To Liver","Metastatic Colon Or Rectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2530271"],"location":["Denmark"],"study_start_month":["4"],"keyword":["Xeloda","irinotecan","oxaliplatin","Avastin"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"Individualised choise of 1.line chemotherapy of metastatic colo-rectal cancer. Can the blood test: TIMP-1 help the doctor to choose the best chemotherapy for the individual patient?","description":"Primary objectives: Aim is to investigate whether or not the cancer marker plasma TIMP-1 is related to probability of treatment response on chemotherapy with or without irinotecan\nPrimary endpoints: Progression free survival (PFS)","dates":{"creation":"2012-04-15"},"accession":"2530271","cross_references":{"EU Clinical Trials Register":["2011-005495-42"]}}